Valiant Laboratories Limited has informed the Exchange regarding Board meeting held on May 20, 2025.
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Valiant Laboratories' board met on May 20, 2025 and approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with an unmodified opinion from statutory auditor Raman S. Shah & Co. On a standalone basis, Q4 FY25 revenue from operations rose sharply to Rs. 5,777 lakhs (vs Rs. 3,058 lakhs in Q4 FY24), while full-year FY25 total income fell to Rs. 13,879 lakhs (vs Rs. 19,173 lakhs in FY24) but net profit improved to Rs. 215 lakhs (vs Rs. 34 lakhs). Consolidated FY25 swung to a net loss of Rs. 220 lakhs (vs Rs. 32 lakhs profit in FY24), largely driven by the subsidiary Valiant Advanced Sciences. The board also re-appointed Ketki D Visariya & Co. as Cost Auditor and Rajesh Chheda & Co. as Internal Auditor for FY 2025-26, and accepted the resignation of Company Secretary & Compliance Officer Ms. Prajakta Patil effective June 15, 2025 to pursue an alternate career. The Audit Committee and Risk Management Committee were reconstituted accordingly.
Mixed results — strong sequential Q4 recovery on the standalone side but a full-year consolidated loss raises concerns about the new subsidiary's performance. The Company Secretary exit is a routine KMP change with a nearly month-long transition, but investors will watch for a timely replacement to ensure no compliance gaps.